Results 241 to 250 of about 4,843,035 (307)

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, EarlyView.
Maxime Fieux, Philippe Gevaert, Leigh J. Sowerby   +2 more
wiley   +1 more source

Increasing Patient Interest in Meniscus Surgery During Last 15 Years With Pain and Recovery Being Most Frequently Searched Topics Online

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To use Google Trends to study whether public interest in meniscus surgery has increased during the last 15 years and after the COVID‐19 pandemic, and to determine what specific topics regarding meniscus surgery the public is interested in. Methods A longitudinal observational study was conducted between January 2010 and December 2024 on public ...
Irfan A. Khan, Tarick Ahmad, Fahad Faheem, Badr Squali‐Houssaini, Dillon Synchef, Brian J. Cole, Paul Phillips IV   +6 more
wiley   +1 more source

Longitudinal evaluation of neurocognitive outcomes in a cohort with persistent post-COVID olfactory dysfunction. [PDF]

Sci Rep
Saak TM, Tervo JP, Jacobson PT, Vilarello BJ, Caruana FF, Gallagher LW, Gary JB, Gudis DA, Motter JN, Goldberg TE, Devanand DP, Overdevest JB.   +11 more
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Evaluation of a multidisciplinary neurological rehabilitation program for the post-COVID-19 condition. [PDF]

J Neurol
Egger M, Strobl R, Vogelgesang L, Reitelbach J, Grill E, Jahn K.   +5 more
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications. [PDF]

J Public Health Afr
Oyebanji O, Falade O, Kristensen F, Heymann D, Kampmann B.   +4 more
europepmc   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source